Cleo Diagnostics Ltd Asset Resilience Ratio
Cleo Diagnostics Ltd asset resilience ratio. Cleo Diagnostics Ltd (COV) has an Asset Resilience Ratio of 94.64% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Cleo Diagnostics Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cleo Diagnostics Ltd (2024–2025)
Asset resilience ratio of Cleo Diagnostics Ltd from 2024 to 2025. This chart shows how Cleo Diagnostics Ltd's Asset Resilience Ratio has changed over time. Read total liabilities of Cleo Diagnostics Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Cleo Diagnostics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Cleo Diagnostics Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$9.43 Million | 94.64% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$9.43 Million | 94.64% |
Asset Resilience Insights
- Very High Liquidity: Cleo Diagnostics Ltd maintains exceptional liquid asset reserves at 94.64% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Cleo Diagnostics Ltd Industry Peers by Asset Resilience Ratio
Compare Cleo Diagnostics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Vitrolife AB
ST:VITR |
Medical Devices | 7.27% |
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 5.73% |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932 |
Medical Devices | 34.47% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
Cleo Diagnostics Ltd Asset Resilience Ratio by Year (2024–2025)
Cleo Diagnostics Ltd asset resilience ratio by year from 2024 to 2025. The table below shows the annual Asset Resilience Ratio data for Cleo Diagnostics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 82.37% | AU$5.71 Million ≈ $4.04 Million |
AU$6.94 Million ≈ $4.91 Million |
+61.62pp |
| 2024-06-30 | 20.75% | AU$2.05 Million ≈ $1.45 Million |
AU$9.88 Million ≈ $6.99 Million |
-- |
About Cleo Diagnostics Ltd
Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing int… Read more